Literature DB >> 3143285

Daytime pulmonary hypertension in patients with obstructive sleep apnea syndrome.

E Weitzenblum1, J Krieger, M Apprill, E Vallée, M Ehrhart, J Ratomaharo, M Oswald, D Kurtz.   

Abstract

The frequency of daytime pulmonary hypertension (PH) in patients with obstructive sleep apnea syndrome (OSAS) has not been well established and its mechanisms are still under debate. We have thus performed right heart catheterization, in addition to standard spirography and arterial blood gas measurements, in a series of 46 consecutive patients in whom OSAS was firmly diagnosed by whole-night polysomnography. Only 9 of the 46 patients (20%) had PH defined by a mean resting pulmonary arterial pressure (Ppa) greater than or equal to 20 mm Hg. Among the patients without resting PH, 14 had exercising PH (defined by a Ppa greater than 30 mm Hg during 40-watt, steady-state exercise). Patients with resting PH differed from the others by a lower daytime PaO2 (60.8 +/- 7.6 versus 76.2 +/- 9.4 mm Hg; p less than 0.001), a higher daytime PaCO2 (44.6 +/- 4.2 versus 38.0 +/- 4.0 mm Hg; p less than 0.001), and lower VC and FEV1 (p less than 0.001). There was no difference between the 2 groups with regard to apnea index (62 +/- 34 versus 65 +/- 40) or the lowest sleep SaO2 (59 +/- 21 versus 66 +/- 18%) or the time spent in apnea. For the group as a whole, there was a good correlation between Ppa and daytime PaO2 (r = -0.61; p less than 0.001), PaCO2 (r = 0.55; p less than 0.001), and FEV1 (r = -0.52; p less than 0.001), but there was no significant correlation between Ppa and the apnea index, the lowest sleep SaO2, or the time spent in apnea.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3143285     DOI: 10.1164/ajrccm/138.2.345

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  35 in total

1.  Effect of treatment by nasal CPAP on cardiopulmonary exercise test in obstructive sleep apnea syndrome.

Authors:  Ching-Chi Lin; Ching-Kai Lin; Kun-Ming Wu; Chon-Shin Chou
Journal:  Lung       Date:  2004       Impact factor: 2.584

Review 2.  Sleep-disordered breathing and COPD: the overlap syndrome.

Authors:  Robert L Owens; Atul Malhotra
Journal:  Respir Care       Date:  2010-10       Impact factor: 2.258

3.  Poor Outcomes Among Patients With Chronic Obstructive Pulmonary Disease With Higher Risk for Undiagnosed Obstructive Sleep Apnea in the LOTT Cohort.

Authors:  Lucas M Donovan; Laura C Feemster; Edmunds M Udris; Matthew F Griffith; Laura J Spece; Brian N Palen; Ken He; Sairam Parthasarathy; Kingman P Strohl; Vishesh K Kapur; David H Au
Journal:  J Clin Sleep Med       Date:  2019-01-15       Impact factor: 4.062

4.  Influence of obstructive sleep apnea on left ventricular mass and global function: sleep apnea and myocardial performance index.

Authors:  Ercan Varol; Selahattin Akcay; Mehmet Ozaydin; Onder Ozturk; Sevim Sureyya Cerci; Unal Sahin
Journal:  Heart Vessels       Date:  2010-07-31       Impact factor: 2.037

5.  Sleep and Obstructive Lung Diseases.

Authors:  Michael E Ezzie; Jonathan P Parsons; John G Mastronarde
Journal:  Sleep Med Clin       Date:  2008-12

6.  [COPD and heart disease].

Authors:  H Watz; M Arzt
Journal:  Herz       Date:  2014-02       Impact factor: 1.443

Review 7.  Sleep apnea, heart failure, and pulmonary hypertension.

Authors:  Sogol Javaheri; Shahrokh Javaheri; Ali Javaheri
Journal:  Curr Heart Fail Rep       Date:  2013-12

Review 8.  [Functional dynamics of the right ventricle and pulmonary circulation in obstructive sleep apnea. Therapeutic consequences].

Authors:  S Steiner; B E Strauer
Journal:  Internist (Berl)       Date:  2004-10       Impact factor: 0.743

Review 9.  Pathophysiology of sleep apnea.

Authors:  Jerome A Dempsey; Sigrid C Veasey; Barbara J Morgan; Christopher P O'Donnell
Journal:  Physiol Rev       Date:  2010-01       Impact factor: 37.312

10.  Pulmonary hemodynamics in obstructive sleep apnea: frequency and causes of pulmonary hypertension.

Authors:  M Hetzel; M Kochs; N Marx; H Woehrle; I Mobarak; V Hombach; J Hetzel
Journal:  Lung       Date:  2003       Impact factor: 2.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.